Megan Glidden Named CFO of Web Industries | Strong Financial Background

Megan Glidden

Web Industries Inc., a global manufacturing partner in the aerospace, medical, personal and home care, and industrial markets, has named Megan Glidden, CPA, as chief financial officer, effective Jan. 15.

“Web Industries conducts business in some of the world’s most dynamic industries,” Glidden said. “I look forward to further advancing our financial functions in ways that not only benefit Web Industries, but also our customers, partners and suppliers.”

Megan Gilden Background

“Megan Gilden comes to Web Industries with a diverse background of foundational roles and business experiences, said Web Industries President and CEO John Madej. We look forward to her contribution to our team.”

Megan Glidden comes to Web Industries from Shirley, Mass.-based Bemis Associates Inc., a privately owned manufacturer, where she most recently served as vice president of finance and global financial planning and analysis (FP&A). Before that, Glidden held finance roles of increasing responsibility at Boston-based McGladrey and Pullen (now RSM), iProspect and Schafer Corp.

She holds a bachelor’s degree in corporate finance and accounting and a master’s degree in accountancy from Bentley University. She also attended the Senior Executive Chief Financial Officer program at Columbia University.

Glidden will be based at Web Industries’ corporate headquarters in Marlborough, reporting directly to Madej.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.